Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$237.57 +1.27 (+0.54%)

As of 01/17/2025 03:59 PM Eastern

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
0

Buy
6

Based on 6 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for BDX.

Consensus Price Target

$283.50
19.33% Upside

According to the 6 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $283.50. The highest price target for BDX is $312.00, while the lowest price target for BDX is $270.00. The average price target represents a forecasted upside of 19.33% from the current price of $237.57.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

BDX Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$283.50	$283.50	$282.63	$278.83
Forecasted Upside	19.33% Upside	24.52% Upside	17.93% Upside	18.20% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.52
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	19.33% Upside	24,741.17% Upside	12.44% Upside
News Sentiment Rating	Positive News See Recent BDX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$286.00 ➝ $290.00	+20.29%
10/1/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$255.00 ➝ $275.00	+14.08%
8/2/2024	Raymond James 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$275.00 ➝ $270.00	+12.55%
7/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$270.00 ➝ $280.00	+17.80%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$274.00	+21.82%
5/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$305.00 ➝ $312.00	+31.85%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$310.00 ➝ $280.00	+17.52%
11/10/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$305.00 ➝ $280.00	+19.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:53 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

The stock has recently been rated as "Moderate Buy" by analysts, indicating positive sentiment and potential for growth.
With a current stock price of $228.46, Becton, Dickinson and Company is trading near its 52-week high of $249.89, suggesting strong market performance.
Evercore ISI has increased the price target for the stock from $286.00 to $290.00, reflecting confidence in the company's future performance.
Insider transactions show that executives are actively managing their shares, with recent sales indicating a strategic approach to stock ownership.
The company has a solid market capitalization of $66.26 billion, which provides stability and resources for growth and innovation in the medical supply sector.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

Recent insider sales, including significant transactions by executives, may raise concerns about the company's short-term outlook and management's confidence in its performance.
The stock has a relatively high P/E ratio of 38.46, which could indicate that it is overvalued compared to its earnings, making it a riskier investment.
Despite a strong market position, the company faces competition in the medical supply industry, which could impact its market share and profitability.
The debt-to-equity ratio of 0.69 suggests that the company is using a moderate amount of debt to finance its operations, which could be a concern if market conditions change.
With only 0.36% of the stock owned by insiders, there may be a lack of alignment between management and shareholder interests, potentially affecting long-term performance.

BDX Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $283.50, with a high forecast of $312.00 and a low forecast of $270.00.
: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BDX shares.
: According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 19.33% based on their 12-month stock forecasts.
: Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:BDX) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target